Summary Using a panel of ten polymorphic markers, we examined the frequency of loss of heterozygosity (LOH) on chromosome 17 in 55 sporadic ovarian tumours. LOH on 17p and 17q was observed to be 50% and 62% respectively. LOH at D17S5 was detected in 24/36 (67%) of malignant cases and in 19/43 (44%) at TP53; the marker D17S855 intragenic to the BRCAJ gene showed allele loss in 50% (20/40) cases. The data presented here suggest that loss of the whole chromosome 17 is a relatively frequent event (30%) in ovarian carcinomas and this observation is especially frequent for serous, transitional cell and anaplastic histological subtypes. Mucinous and endometrioid ovarian tumours showed only short interstitial deletions (4/11, 36%). The overall frequency of the short deletions was relatively low (7/43, 16%) in our panel of carcinomas. Amplification of c-erbB-2/neu oncogene was detected in 32% (11/34) of the carcinomas tested; the gene was amplified only in those histological subtypes in which high incidence of LOH on chromosome 17 was observed, and was associated with advanced stages of the disease. We conclude that different histological types of tumour may have different aetiological mechanisms, and tumour-suppressor genes on chromosome 17 might be associated specifically with serous and transitional cell ovarian carcinomas.
Molelcular genetic analysis of ovarian carcinomas has revealed a significant role for chromosome 17 in pathogenesis of ovarian malignancies. These studies have shown that loss of heterozygosity (LOH) for regions of chromosome 17 is a frequent event, probably indicating the inactivation of suppressor genes present on this chromosome (Eccles et al., 1990; Lee et al., 1990; Russell et al., 1990; Foulkes et al., 1991; Phillips et al., 1993) . The search for loss of constitutional heterozygosity with polymorphic genetic markers is now a widely accepted approach to indicate areas on the genome where inactivation of tumour-suppressor genes may occur.
The p53 tumour-suppressor gene is the most commonly mutated gene in human cancer (Greenblatt et al., 1994) , and LOH on 17p at or close to the p53 locus is present very frequently in ovarian carcinomas (Okamoto et al., 1991; Tsao et al., 1991; Eccles et al., 1992a; Cliby et al., 1993; Foulkes et al., 1993; Yang-Feng et al., 1993) .
The breast and ovarian cancer susceptibility locus, BRCA1, has been cloned from the chromosomal region 17q21 (Miki et al., 1994) . The first mutations of the BRCAI gene observed in sporadic ovarian carcinomas have recently been reported (Merajver et al., 1995) . Frequent losses in this region (at 17ql2-23) and at a more distally located locus (at 17q22-23) have been observed (Hall et al., 1990; Narod et al., 1991; Jacobs et al., 1993; Saito et al., 1993; Cornelis et al., 1995) .
In addition to the studies addressing the importance of specific tumour-suppressor genes, several groups examined the frequency of oncogenes activated in ovarian carcinomas. Amplification of the c-erbB-2/neu oncogene was observed most frequently, and was associated with advanced stages and poor clinical outcome (Slamon et al., 1989) . In order to contribute to the clarification of the biological significance of genetic alterations on chromosome 17 in ovarian cancer, in this study we further examined the amplification of c-erbB-2 oncogene and the frequencies of losses of heterozygosity at ten different loci on chromosome 17 in 50 epithelial and in five non-epithelial ovarian tumours. step PCR amplification protocol decribed by Jones and Nakamura (1992) . In all cases, PCR cycles were preceded by an initial denaturation step (10 min at 95°C) and followed by an elongation step (7 min at 72°C). PCR products of microsatellite markers were run on a standard sequencing gel using an M13 sequencing reaction as size marker. After fixation and drying, gels were autoradiographed for 1 -3 days at room temperature. Amplified fragments of the YNZ22 marker with VNTR polymorphism were run on 2% agarose (SeaKem) gel and visualised by ethidium bromide staining.
Materials and methods

Samples
Statistical analysis All comparisons between groups and/or parameters were performed using Fisher's exact t-test. One-tailed Pvalues<0.05 were considered statistically significant.
Results
After characterising all 55 cases of primary tumours of the ovary by histology and grade, DNA extracted from tumours and corresponding normal DNAs were screened for allele loss of both arms of chromosome 17 using ten polymorphic markers. The informativity of the markers and the frequencies of LOHs are summarised in Table I . The pattern of losses is presented in Figure 1 . In non-epithelial ovarian tumours allelic deletion was relatively common; three out of five non-epithelial malignant tumours showed deletions affecting only one marker (TP53) in one case and long chromosomal fragments in the two other cases. Figure  2) . Loss of the entire chromosome 17 was found in 30% (13/ 44) of carcinomas examined. In contrast, only one of four mucinous and three of six endometrioid tumours presented allelic deletions, affecting only one or two markers in each case. The overall frequency of short, interstitial deletions was relatively low (7/43, 16%) in our panel of malignant tumours.
To elucidate the genetic imbalance of ovarian carcinoma cells further, amplification of the c-erbB-2 oncogene, which is associated with poor prognosis in ovarian as well as in breast carcinomas, was also evaluated (Figures 1 and 3) . The frequency of amplification of this gene in our ovarian tumours was determined and related to the clinical stage and histological grade of the disease. We found 2-5-fold amplification of the c-erbB-2 oncogene in 11 of 34 (32%) of the carcinomas and neither benign tumours nor non-epithelial malignant cases showed c-erbB-2 amplification (Table II) . All tumours, except one containing amplified c-erbB-2, were of advanced stage, and amplification of c-erbB-2 was associated (P= 0.011) with higher grade. c-erbB-2 was found to be amplified only in those histological subtypes, in which high incidence of LOH on chromosome 17 was observed. whole copy of the chromosome 17 suggests the possible involvement of multiple chromosome 17 loci in the pathogenesis in some ovarian tumours. This is consistent with the presence of tumour-suppressor genes on both arms of this chromosome, including p53, BRCAJ and a potential tumour-suppressor gene distal to BRCAI (Jacobs et al., 1993; Godwin et al., 1994) .
Specifically, all losses of the whole chromosome 17 and the vast majority of losses of large chromosomal regions were detected in serous, anaplastic, transitional cell or mixed cell ovarian carcinomas. It is noteworthy that serous carcinoma samples without any loss (cases 53, 58, 90 and 92) 52 and 60 demonstrate more than 2-fold amplification. The same LOH on the short arm of the chromosome, including the filter was reprobed with the GAPDH probe (lower panel); Co, p53 locus, was observed in ovarian carcinomas by several normal lymphocyte control.
groups (Coles et al., 1990; Eccles et al., 1992b; Kohler et al., 1993) . In our studies there was 50% LOH at p53. Allelic losses and mutations of the p53 gene are common genetic Discussion events in ovarian cancer (Okamoto et al., 1991; Millner et al., 1993) , indicating a direct involvement of p53 in ovarian Very frequent LOH occurred at all chromosome 17 loci malignancies. On the basis of LOH studies, several reports examined in this study. In contrast to reports on chromosome have suggested that in addition to p53 there may be a gene 17 in breast cancer (Lindblom et al., 1993) and other telomeric of p53 (at 17pl3.3), which is acting as a tumour chromosomes involved in ovarian carcinogenesis (e.g. suppressor or a regulator of p53 expression in breast an-d chromosome 6) (Wan et al., 1994) , in which LOH affects ovarian carcinogenesis (Tsao et al., 1991; Wales et al., 1995; only Figure 2 .) Allelic losses on 17p have been observed in various malignancies, but LOH on 17q appears to be more specific for breast and ovarian carcinomas. The familial breast/ ovarian cancer locus (BRCA1) is mapped to 17q21, and the BRCAI gene has already been isolated (Miki et al., 1994) . In a multicentre study, we recently reported LOH in 86% of familial breast and ovarian tumours, which invariably involved the wild-type allele (Cornelis et al., 1995) . These results strongly support the case that BRCAJ is a tumoursuppressor gene and the loss of heterozygosity is greatly favoured to inactivate it fully. Somatic point mutations in BRCAJ are relatively infrequent in sporadic breast and ovarian cancer, but deletion of one BRCAJ allele occurs in approximately 50% of sporadic breast and 70% of sporadic ovarian cancer (Futreal et al., 1994; Merajver et al., 1995; Holt et al., 1996) Pieretti et al. (1995) .
In our studies the c-erbB-2/neu locus was found to be amplified in 32% of the malignant cases and c-erbB-2 amplification was more characteristic of higher histological grade and clinical stage. These results are in agreement with the report of Slamon et al. (1989) , who first demonstrated a relationship between c-erbB-2 amplification and poor prognosis for ovarian as well as breast carcinomas. The c-erbB-2 gene was amplified only in those histological subtypes (serous, anaplastic, transitional cell and mixed cell) in which high incidence of LOH occurred. In 10 out of 11 cases, both amplification and loss of the same region (D17S250, THRAI) were observed. The term allelic imbalance, introduced by Devilee and Cornelisse (1994) , would provide a better description of such DNA changes as it permits interpretation of imbalance of allelic signals, irrespective of whether it is an allelic loss or gain.
The data presented here further suggest that allelic imbalance of chromosome 17 is an important genetic event in epithelial ovarian carcinogenesis. Our results also indicate that there might be different genetic pathways in the aetiology of histological subtypes of ovarian cancer.
